18 completed, 4 terminated, 2 unknown. 24 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 18, Terminated 4, Unknown 2 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Brimonidine Tartrate: new trials by email Literature Review of Brimonidine Tartrate trials Research Report on Brimonidine Tartrate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle proprietary ophthalmic solution - Presbyopia, Refractive Errors | Phase 2 | Completed | LENZ Therapeutics, Inc | 59 | 2022-08-06 | 2024-09-05 |
| Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle Proprietary Ophthalmic Solution - Presbyopia, Refractive Errors | Phase 2 | Completed | LENZ Therapeutics, Inc | 68 | 2022-05-05 | 2024-09-05 |
| Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia BRIMOCHOL™, BRIMOCHOL™ F, Carbachol - Presbyopia | Phase 2 | Completed | Visus Therapeutics | 18 | 2021-03-24 | 2026-03-27 |
| Pupil Dilation for Treatment of IFIS Brimonidine Tartrate - Intraoperative Floppy Iris Syndrome | Phase 2 | Completed | Denver Health and Hospital Authority | 13 | 2019-01-04 | 2022-04-20 |
| The Effectiveness of Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle Glaucoma Drugs, Investigational - To See the Safety and Efficacy of the Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle Glaucoma Patients | Phase 2 | Completed | Chittagong Medical College | 80 | 2018-06-25 | 2019-12-26 |
| Dry Eye Disease Study With Brimonidine Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose - Dry Eye | Phase 2 | Completed | Ocugen | 84 | 2017-09-06 | 2022-07-06 |
| The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients Brimonidine Tartrate - Hand-foot Syndrome | Phase 2 | Terminated | Heinrich-Heine University, Duesseldorf | 2 | 2017-07-10 | 2019-01-09 |
| Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD) Brimonidine 0.15%, Brimonidine 0.075%, Placebo - Dry Eye, Ocular Graft vs Host Disease | Phase 1 / Phase 2 | Terminated | Sandeep Jain, MD | 15 | 2016-05-01 | 2019-11-08 |
| The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter Combigan (Combination of Brimonidine and Timolol), Timolol - Healthy | Phase 2 | Unknown | Carmel Medical Center | 25 | 2015-10-01 | 2015-10-14 |
| A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration 400 µg Brimonidine Implant, Sham - Geographic Atrophy, Macular Degeneration | Phase 2 | Terminated | Allergan | 310 | 2014-05-09 | 2019-04-23 |
| A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension Fixed-Combination Bimatoprost/Brimonidine, Bimatoprost Ophthalmic Solution 0.01%, Vehicle Ophthalmic Solution - Glaucoma, Ocular Hypertension | Phase 2 | Completed | Allergan | 112 | 2013-06-01 | 2015-01-26 |
| Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy COLIRIOBCN070660, Placebo, Brimonidine - Diabetic Retinopathy | Phase 2 / Phase 3 | Completed | BCN Peptides | 450 | 2013-02-01 | 2016-01-12 |
| A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2% Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2% - Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Alcon Research | 103 | 2011-09-01 | 2013-07-08 |
| Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy Brimonidine, Placebo Lotion - Glaucoma | Phase 2 | Unknown | Nanduri, Padma, M.D., FACS | 22 | 2011-04-01 | 2011-05-02 |
| Transconjunctival Needling Revision Versus Medical Treatment Transconjunctival needling revision, Medical treatment - Primary Open Angle Glaucoma | Phase 2 | Completed | University of Sao Paulo General Hospital | 40 | 2010-05-01 | 2013-06-27 |
| Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function 400 ug Brimonidine Implant, 200 ug Brimonidine Implant, Sham (no implant) - Rhegmatogenous Macula-off Retinal Detachment | Phase 2 | Completed | Allergan | 44 | 2009-11-01 | 2013-04-24 |
| Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2% - Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Terminated | Alcon Research | 195 | 2009-10-01 | 2013-07-04 |
| Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy 400 ug Brimonidine Implant, 200 ug Brimonidine Implant, Sham (no implant) - Glaucoma, Open-Angle | Phase 2 | Completed | Allergan | 70 | 2008-09-01 | 2013-04-24 |
| An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa 400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant, 100 µg Brimonidine Tartrate Implant - Retinitis Pigmentosa | Phase 1 / Phase 2 | Completed | Allergan | 21 | 2008-07-01 | 2013-04-24 |
| Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Acetazolamide, Brimonidine tartarate, Anterior chamber paracentesis - Age Related Macular Degeneration, Diabetic Retinopathy | Phase 2 | Completed | University of Sao Paulo | 56 | 2008-06-01 | 2009-03-19 |
Showing 20 of 24. Sign in to see all of them.
Glaucoma, Open-Angle (4) · Macular Degeneration (4) · Ocular Hypertension (4) · Diabetic Retinopathy (3) · Glaucoma (3) · Presbyopia (3) · Dry Eye Syndromes (2) · Eye Diseases (2) · Myopia (2) · Refractive Errors (2) · Geographic Atrophy (1) · Hand-Foot Syndrome (1) · Macular Edema (1) · Meibomian Gland Dysfunction (1) · Retinitis Pigmentosa (1)
Allergan (7) · Alcon Research (2) · LENZ Therapeutics, Inc (2) · University of Sao Paulo (2) · BCN Peptides (1) · Carmel Medical Center (1) · Chittagong Medical College (1) · Denver Health and Hospital Authority (1) · Galderma R&D (1) · Heinrich-Heine University, Duesseldorf (1) · Nanduri, Padma, M.D., FACS (1) · Ocugen (1) · Sandeep Jain, MD (1) · University of Sao Paulo General Hospital (1) · Visus Therapeutics (1)
United States (15) · Germany (5) · France (3) · Israel (3) · Italy (3) · Portugal (3) · United Kingdom (3) · Australia (2) · Brazil (2) · Philippines (2) · South Korea (2) · Bangladesh (1) · Denmark (1) · India (1) · Spain (1)
Alisyn Facemire, BA (2) · Bianka Y Katayama, MD (1) · Claire Winterson (1) · Cristos Ifantides, MD (1) · James Leyden, M.D. (1) · James Teague, BS, Sr. Clinical Manager (1) · Marco A Bonini-Filho, MD (1) · Michael Boone, MD (1) · Orna Geyer, MD (1) · Padma Nanduri, MD (1) · Peter Arne Gerber, PD Dr. med. (1) · Ravaughn Williams, OD, MS (1) · Remo Susanna Jr., MD (1)
PMID 32134802, PMID 24212847, PMID 28663190, PMID 28785768, PMID 33383315, PMID 9261306